Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models

Background: The multikinase inhibitor regorafenib, approved as second-line treatment for hepatocellular carcinoma (HCC) after sorafenib failure, may induce mitochondrial damage. BH3-mimetics, inhibitors of specific BCL-2 proteins, are valuable drugs in cancer therapy to amplify mitochondrial-depende...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancers (Basel)
Glavni autori: Cucarull, Blanca, Tutusaus, Anna, Subías, Miguel, Stefanovic, Milica, Hernáez-Alsina, Tania, Boix, Loreto, Reig, María, García de Frutos, Pablo, Marí, Montserrat, Colell, Anna, Bruix, Jordi, Morales, Albert
Format: Artigo
Jezik:Inglês
Izdano: MDPI 2020
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7073154/
https://ncbi.nlm.nih.gov/pubmed/32024199
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12020332
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items